EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,428 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
Follow-Up Questions
What is the price performance of EAPIF stock?
The current price of EAPIF is $3.59, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Euroapi SA?
Euroapi SA belongs to Pharmaceuticals industry and the sector is Health Care
What is Euroapi SA market cap?
Euroapi SA's current market cap is $341.8M
Is Euroapi SA a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Euroapi SA, including 0 strong buy, 1 buy, 4 hold, 6 sell, and 0 strong sell
